melanotan ii mastery course
Unit 2 of 11

receptor pharmacology and selectivity

why hitting four receptors at once creates effects you didn't ask for

non-selective binding is the story

Melanotan II's defining pharmacological feature is that it does not pick a single melanocortin receptor. It activates MC1R, MC3R, MC4R, and MC5R with meaningful affinity. That non-selectivity is responsible for both the tanning effect and every off-target consequence that follows.

interactive receptor binding map

explore how MT-II distributes its binding across four melanocortin receptor subtypes and what each receptor mediates.

receptor binding map

receptor binding snapshot

quick reference for MT-II's affinity at each melanocortin receptor subtype.

Ki ~0.67 nM
MC1R binding affinity -- highest target, drives pigmentation
Ki ~34 nM
MC3R binding -- energy homeostasis and appetite modulation
low nM
MC4R binding -- appetite suppression and sexual function
>1 uM
MC2R binding -- essentially none, spares adrenal cortisol
MT-II is a full agonist at MC1R, MC3R, MC4R, and MC5R simultaneously. This non-selectivity is a pharmacological fact of its cyclic structure -- not a dosing problem. Lowering the dose reduces all receptor-mediated effects proportionally; it does not create selectivity for any single receptor.

key terms

core vocabulary for this unit.

M1 MC1R melanocortin 1 receptor
The pigmentation receptor, expressed on melanocytes. MT-II binds MC1R with sub-nanomolar affinity (Ki ~0.67 nM), triggering the cAMP-MITF-tyrosinase cascade that produces eumelanin. This is the tanning receptor.
M3 MC3R melanocortin 3 receptor
Found in the hypothalamus, gut, and placenta. Involved in energy homeostasis and nutrient partitioning. MT-II activates MC3R at Ki ~34 nM, contributing to appetite modulation.
M4 MC4R melanocortin 4 receptor
Expressed in the hypothalamus and other CNS regions. Mediates appetite suppression and sexual function. The receptor behind MT-II's unexpected erectile effects that led to PT-141 development. Loss-of-function mutations in MC4R cause severe early-onset obesity.
M5 MC5R melanocortin 5 receptor
Expressed in exocrine glands, particularly sebaceous glands. Involved in sebum production and thermoregulation. The least studied melanocortin receptor; clinical significance of MT-II activation here is unclear.
M2 MC2R ACTH receptor
The ACTH receptor on the adrenal cortex. Requires the accessory protein MRAP for proper function. MT-II has negligible binding here (Ki >1 uM), which is an important safety feature -- no cortisol stimulation.
FA full agonist pharmacology
MT-II produces maximal receptor activation at saturating concentrations at MC1R, MC3R, MC4R, and MC5R. This means it is not a partial agonist -- at sufficient doses, it drives each receptor to its maximum possible signaling output.

receptor pharmacology -- the simple version

why MT-II does more than just tanning, explained plainly.

Your body has five melanocortin receptors, each controlling different functions. MT-II activates four of them at once. MC1R controls skin pigmentation -- this is the tanning receptor. MC3R and MC4R, located in the brain, control appetite and sexual function. MC5R affects glands in the skin. The one receptor MT-II does not activate is MC2R, which controls cortisol production in the adrenal glands -- this is an important safety feature. Because MT-II hits four receptors simultaneously, you cannot get tanning without also affecting appetite, sexual function, and potentially other systems. Lowering the dose reduces all effects equally; it does not make the peptide more selective. This non-selectivity is a fixed property of its chemical structure, not something that can be adjusted.

A advanced: binding affinities and the selectivity problem term
MT-II binds MC1R with sub-nanomolar affinity (Ki ~0.67 nM), MC4R in the low nanomolar range, MC3R at ~34 nM, and MC5R in the nanomolar range. The affinity differences between these receptors span only about a 50-fold range -- far too narrow to exploit with dose adjustments. For comparison, a truly selective drug would have 1000-fold or greater affinity differences between target and off-target receptors. At any dose that meaningfully activates MC1R for tanning, MC4R and MC3R are also substantially engaged. Functional cAMP accumulation assays confirm that MT-II is a full agonist at all four receptors, producing maximal signaling output at saturating concentrations.
advanced: MC4R and centrally-mediated sexual function
MC4R activation in the hypothalamus mediates both appetite suppression and sexual arousal. The sexual mechanism is fundamentally different from PDE5 inhibitors like sildenafil, which act peripherally on blood vessel smooth muscle. MT-II acts centrally in the brain, modulating both the physiological response (erection, genital arousal) and the psychological component (desire and motivation). This is why MT-II can produce arousal without sexual stimulation. The Wessells 1998 study found erections in 8 of 10 men with psychogenic ED, with mean tip rigidity exceeding 80% for 38 minutes on MT-II versus 3 minutes on placebo. This MC4R pathway led directly to development of bremelanotide (PT-141/Vyleesi).
advanced: why MC2R is spared
MC2R is the only melanocortin receptor that requires an accessory protein called MRAP (melanocortin 2 receptor accessory protein) for proper cell-surface expression and ligand binding. MRAP shapes the MC2R binding pocket in a way that strongly favors ACTH over other melanocortin ligands. MT-II's cyclic structure does not fit this MRAP-dependent conformation, resulting in negligible binding (Ki >1 uM, roughly 1000-fold lower than for MC1R). If MT-II activated MC2R, it would stimulate adrenal cortisol release, potentially causing Cushing's-like symptoms -- weight gain, immunosuppression, and hypertension. This structural incompatibility is an unintentional but critical safety feature.

selectivity matters

the drugs that emerged from MT-II research each solved the selectivity problem that MT-II itself never solved.

afamelanotide (MT-I)
MC1R-selective, linear 13aa. FDA/EMA approved for EPP. pigmentation without sexual/appetite side effects.
melanotan II
non-selective, cyclic 7aa. never approved. tanning + appetite + sexual effects + nausea. cannot isolate any single effect.
bremelanotide (PT-141)
MC4R-preferring, cyclic. FDA approved for HSDD. sexual effects with less pigmentation. MT-II metabolite.